Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Citi Resumes Sensei Biotherapeutics (SNSE) at Buy, 'Initial SNS-101 Efficacy Data at ASCO Suggest Early Clinical Activity'
June 3, 2024 2:00 PM EDTCiti analyst Samantha Semenkow resumes coverage on Sensei Biotherapeutics (NASDAQ: SNSE) with a Buy rating and a price target of $4.00.
The analyst comments "We resume coverage after a period of Rating Suspended with a Buy/High Risk rating and $4/shr TP. At ASCO, Sensei... More



